omeprazole / Generic mfg. - LARVOL DELTA

Fulzerasib in Combination With Omeprazole Pretreatment and/or Terbinafine in KRAS G12C Mutant Lung Cancer Cell Lines (IASLC-WCLC 2026) - "Introduction : Fulzerasib plus cetuximab demonstrate significant clinical outcomes in KRAS G12C-mutant NSCLC patients (Gregorc et al. Western blot analysis confirms the broad shutdown effect of the triple combination on multiple receptors and critical downstream effectors that confer resistance to KRAS G12C inhibitors. Clinical translational relevance warrants being highlighted."

Combination therapy • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • AURKA • EGFR • HES1 • KEAP1 • KRAS • SOX2 • SQLE • STK11

Treating Ménétrier's Disease With Cetuximab (ACG 2026) - "She had no improvement in symptoms with?Omeprazole, Carafate, or?Vonaprazan.?Her?labs were notable for Hgb 13.8, albumin 4.5, lipase 40, negative CMV PCR, normal gastrin and ACE level, and negative H pylori stool antigen. Thickened Gastric Folds on Esophagogastroduodenoscopy in Gastric Body Figure: Figure 2. Marked Foveolar Hyperplasia on Pathology Slides from Full Thickness Biopsy"

Gastric Adenocarcinoma • Infectious Disease • Solid Tumor • EGFR • GAST

Pan-RAS(on) Inhibitors RMC-6236 and GFH276 With Omeprazole or Ensartinib in KRAS-mutant Lung Cancer Cells (IASLC-WCLC 2026) - "Our previous work showed that the combination of omeprazole plus tepotinib is active in KRAS-mutant G12C and non-G12C cell lines ( Rosell et al...The H23 and A549 (sotorasib-resistant) cells were sensitive to both Pan-RAS(ON) inhibitors with higher IC 50s...Finally, pretreatment with omeprazole plus Pan-RAS inhibitors suggests a potential to delay resistance. Like crizotinib, ensartinib has activity against ALK, ROS1, and MET, and additionally targets AXL; therefore, ensartinib warrants further investigation."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • AXL • CTNNB1 • KRAS • ROS1 • SQSTM1 • STAT3

Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft. (PubMed, Neoplasia) - "XPO1 protein suppression is not achieved with sotorasib alone in KRAS G12C NSCLC cells. Notably, the combination of sotorasib, selinexor, and omeprazole abolishes the expression of XPO1, AURKA, YAP, and MRAS. The feasibility of therapy with XPO1 inhibition plus KRAS inhibitors warrants clinical exploration."

IO biomarker • Journal • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BIRC5 • EGFR • KRAS • XPO1 • YAP1

INAVO121: A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (clinicaltrials.gov) - P3 | N=420 | Recruiting | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • HER-2 • PIK3CA

Preparation of Deuterium-Labeled Tadalafil and Omeprazole by Carbon Hydrogen-Deuterium Exchange: Hydrogen Scrambling, Acid-Induced Transformation, and LC-MS Applications. (PubMed, Rapid Commun Mass Spectrom) - "Base-catalyzed carbon hydrogen-deuterium exchange provides a rapid and cost-effective approach for preparing stable isotope-labeled tadalafil and omeprazole suitable for LC-MS applications. The study further demonstrates that carbon-bound deuterium constitutes a valuable mechanistic probe, enabling investigation of hydrogen scrambling during tandem mass spectrometry and evaluation of isotope-label stability during acid-induced molecular transformation. The combined HRMS, tandem MS, NMR, and DFT approach establishes a comprehensive framework for characterization of deuterium-labeled compounds and supports their future application in quantitative analysis as well as structural elucidation by mass spectrometry."

Journal

A complementary dual-platform analytical strategy for resolving matrix effects and stability limitations in bioanalysis. (PubMed, Front Vet Sci) - "The complementary use of HPLC and UHPLC-MS/MS provided both characterization of compound-specific analytical behavior and sensitive quantification of trace drug concentrations in equine plasma. This analytical framework may support pharmacokinetic studies of famotidine and omeprazole in equine models."

Journal

Computational, In Vitro, and In Vivo Evaluation of Benzimidazole-Pyrazole Hybrid Scaffolds as Multi-Target Anti-Ulcer Agents. (PubMed, Chem Biodivers) - "Molecular docking into H+/K+-ATPase (PDB ID: 5YLU) and COX-2 (PDB ID: 3LN1) enzymes predicted high affinity of these compounds with docking scores of -9.4 and -9.3 kcal/mol for compounds 5i and 5e, respectively, higher than those obtained for the reference drugs omeprazole and celecoxib...Studies on the ethanol and indomethacin-induced gastric ulceration models demonstrated good inhibitory effects of these compounds...Acute oral toxicity studies indicated no observable toxicity at 100 mg/kg. Collectively, these findings identify compounds 5i and 5e as promising multifunctional gastroprotective candidates warranting further pharmacological investigation."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Peptic Ulcer • MPO • TNFA

Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants (clinicaltrials.gov) - P1 | N=54 | Completed | Sponsor: Epygenix

New P1 trial

Potential Drug-Drug Interactions in Patients Undergoing Hemodialysis: A Retrospective Observational Study. (PubMed, Saudi Med J) - "In total, 4,157 pDDIs were identified, most of which were Category C (75.4%), followed by Categories B and D. Category X interactions were uncommon (n = 78), with clopidogrel-omeprazole and clopidogrel-esomeprazole being the most frequent. The pDDIs are highly prevalent among patients with ESRD undergoing HD, with polypharmacy identified as the main determinant. These findings highlight the importance of structured medication review, multidisciplinary collaboration, and clinical pharmacist involvement to reduce medication-related risks and optimize patient outcomes."

Journal • Observational data • Retrospective data • Chronic Kidney Disease • Nephrology • Renal Disease

Association Between Gastroesophageal Reflux and Post-Tympanostomy Tube Otorrhea in Children (AAO-HNSF 2026) - "GER was associated with increased rates of otorrhea following tympanostomy tube placement in children, suggesting reflux management as a modifiable factor in perioperative management."

Clinical • Allergic Rhinitis • Asthma • Gastroenterology • Gastroesophageal Reflux Disease • Immunology • Inflammation • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Stability Evaluation of Compounded Multidrug Oral Liquids in a Dual-Vehicle Suspending System. (PubMed, Int J Pharm Compd) - "This study evaluated the chemical, physical, and microbiological stability of formulations containing topiramate, omeprazole, gabapentin, ondansetron, and levofloxacin prepared in Flavor Sweet™ SF and Flavor Plus™, also known as Syra Sweet™ SF and Syra Plus™. All formulations showed consistent pH and acceptable microbiological quality, although precipitation in some samples led to discontinuation of analysis. These results support the suitability of the vehicle system and highlight the importance of formulation parameters in stability and beyond-use dating."

Journal

Effects of Kudzu Root (Gegen) on Drug-Metabolizing Enzymes and Blood Clotting in Healthy Volunteers (clinicaltrials.gov) - P1 | N=56 | Completed | Sponsor: Chinese University of Hong Kong

Biomarker • New P1 trial • Thrombosis • CYP2C19 • CYP2C9 • CYP3A4

Rutin loaded nanosponges for treatment of peptic ulcer: in silico, pharmacodynamic and pharmacokinetic studies. (PubMed, AAPS PharmSciTech) - "RTN-NS₄ achieved 42 ± 7.23% ulcer inhibition in ethanol-induced gastric ulcers in Wistar rats, surpassing RTN (22.17 ± 6.53%) but 18% lower than omeprazole (60.16 ± 8.23%). Histological studies confirmed moderate mucosal protection and reduced inflammation in RTN-NS₄-treated rats. These results underscore RTN-NS₄ as promising nanophyto-therapeutic system offering synergistic antioxidant, anti-inflammatory and PPI activity effects for effective ulcer management without the concomitant side effects of PPIs."

Journal • PK/PD data • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Inflammation • Peptic Ulcer

Cost-effectiveness analysis of omeprazole for preventing esophageal stricture in patients with Zargar grade 2b and 3a corrosive esophageal injuries: A trial-based economic evaluation. (PubMed, Medicine (Baltimore)) - "Omeprazole plus standard treatment may represent a cost-effective strategy for adult patients with Zargar grade 2b and 3a corrosive esophageal injuries. However, these findings should be considered preliminary and require confirmation in larger multicenter randomized controlled trials."

Clinical • HEOR • Journal

Prevalence of pharmacogenomically implicated prescriptions in multi-ethnic populations in Singapore. (PubMed, Br J Clin Pharmacol) - "Pharmacogenomically implicated medication prescriptions are common in Singapore and are particularly prevalent in elderly populations. Strategic investments in infrastructure and policy development will be pivotal to the successful integration of pre-emptive PGx into clinical practice."

Biomarker • Journal • CYP2C19

Influence of fluoxetine on the gastric healing process: experimental evidence of sexual dimorphism. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Two days after ulcer induction, animals received vehicle (water, 1 mL/kg), omeprazole (20 mg/kg), or fluoxetine (0.17 or 1.7 mg/kg) orally once daily for seven days. Furthermore, the tested doses did not affect gastric acidity, volume, or peptic activity in pylorus-ligated rats. These findings demonstrate that fluoxetine promotes gastric ulcer healing in male rats, possibly by enhancing mucosal barrier defenses and attenuating inflammation, while no healing effect was observed in females, suggesting a sex-dependent response."

Journal • Inflammation • Peptic Ulcer • MPO

Evaluation of the Effect of Cendakimab on the Pharmacokinetics of CYP Probe Drugs in Patients With Eosinophilic Esophagitis. (PubMed, Clin Transl Sci) - "Patients received a cocktail of probe substrates (caffeine 200 mg, warfarin 10 mg + vitamin K 10 mg, omeprazole 40 mg, dextromethorphan 30 mg, midazolam 5 mg) for cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A in two sequential periods, separated by 16 weeks of cendakimab treatment. No clinically relevant changes in laboratory tests, vital signs, or electrocardiograms were observed. Cendakimab had no clinically meaningful effects on cytochrome P450 enzyme activities and was generally safe and well tolerated with or without probe substrates in adults with active eosinophilic esophagitis."

Journal • PK/PD data • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology • Inflammation • IL13

When Rising Thyroglobulin Does Not Mean Cancer Recurrence: The Impact of Graves’ Disease on Thyroid Remnants (ETA 2026) - "At the age of 51, she developed GD and failed to achieve remission with methimazole (MM), leading to left hemithyroidectomy...Medication included levothyroxine 100µg od, methotrexate, folic acid, cyclobenzaprine and omeprazole... In this case, considering the low risk of PTC recurrence, autoimmune stimulated growth of residual thyroid tissue causing Tg increasing levels was the most likely diagnosis. However, it illustrates the diagnostic challenge of interpreting laboratory and sonography findings in patients with differentiated follicular cell-derived thyroid cancer and concomitant GD. Awareness of the described pitfalls is essential to prevent misinterpretation and avoid unnecessary interventions."

Endocrine Disorders • Fibromyalgia • Grave’s Disease • Immunology • Inflammatory Arthritis • Musculoskeletal Pain • Oncology • Rheumatoid Arthritis • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma • TG

Beyond acid suppression: the multifaceted role of proton pump inhibitors in Helicobacter pylori eradication. (PubMed, Front Microbiol) - "This review provides a comprehensive overview of the pharmacological properties, clinical applications, and current limitations of the most widely used PPIs, including omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, and rabeprazole. The review also discusses emerging evidence for interindividual variability in PPI metabolism, drug-drug interactions, and concerns regarding long-term adverse effects of the current treatments. Finally, it highlights potassium-competitive acid blockers (P-CABs), a newer class of acid-suppressive agents that provide sustained acid inhibition and represent a promising alternative to PPI-based regimens for H. pylori eradication."

Journal • Review • Infectious Disease

Proton Pump Inhibitors in Glioblastoma: From Reflexive Prescribing to Evidence-Based Practice. (PubMed, J Pak Med Assoc) - "Emerging evidence suggests that exposure to PPIs with potent aldehyde dehydrogenase 1A1-activating properties (PA-PPIs) such as omeprazole may be associated with worse progression-free and overall survival in newly diagnosed glioblastoma (GBM)...When acid suppression is clinically indicated, the choice of agent should be individualized, with consideration of H₂ receptor antagonists or antacids where appropriate. These findings support an acid-suppressive stewardship approach in the management of patients with GBM."

Journal • Review • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Isolated Collagenous Gastritis With Biopsy-Confirmed Histologic Resolution Following Etodolac Cessation in an Adult With Psoriatic Arthritis and Atopic Diathesis (ACG 2026) - "Medication included chronic daily etodolac, adalimumab, and valsartan...An empiric 8-week course of pantoprazole 40mg twice daily failed to improve symptoms...Without an identifiable etiology, etodolac was discontinued, and therapy was transitioned to omeprazole 40mg twice daily...(A) Initial evaluation demonstrating diffuse moderate inflammation with erythema, edema, erosions, and friability of the gastric body. (B) Follow-up endoscopy after etodolac cessation showed a more uniform mucosal surface with reduced erythema and fewer erosive changes."

Biopsy • Clinical • Allergic Rhinitis • Atopic Dermatitis • Celiac Disease • Dermatitis • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

A Case of Esophagitis Dissecans Superficialis in a Patient With Crohn's Disease (ACG 2026) - "Case Description/ We report the case of a 27-year-old male diagnosed with ileocolonic and upper gastrointestinal Crohnâs Disease (CD) at age 22, treated with adalimumab since diagnosis...His medical history was also notable for a psoriasiform rash managed with topical corticosteroids and major depressive disorder managed with fluoxetine...The patient was started on an 8-week course of omeprazole twice daily, followed by once-daily dosing for an additional 4 weeks...Figure: Upper third of the esophagus demonstrating circumferential sloughing and peeling of the superficial esophageal mucosa consistent with esophagitis dissecans superficialis (EDS). Figure: Middle third of the esophagus demonstrating extensive mucosal desquamation with longitudinal strips of sloughed superficial mucosa consistent with esophagitis dissecans superficialis (EDS)."

Clinical • CNS Disorders • Crohn's disease • Depression • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Major Depressive Disorder

Differential fracture risk among proton pump inhibitors in older adults: evidence network and pharmacovigilance validation. (PubMed, Front Pharmacol) - "Compared with non-PPI users, omeprazole (OR 1.51, 95%CI 1.36-1.67), rabeprazole (OR 1.47, 95%CI 1.22-1.78), pantoprazole (OR 1.44, 95%CI 1.28-1.62), and lansoprazole (OR 1.32, 95%CI 1.14-1.53) were associated with a significantly increased risk of any-site fracture...Consistent with NMA findings, omeprazole exhibited a significant fracture risk signal (ROR 1.25, 95%CI 1.03-1.51), while esomeprazole showed no significant signal for overall fracture (ROR 0.89, 95%CI 0.66-1.20)...This discordance indicates that absence of a fracture signal should not imply skeletal safety. These findings provide evidence-based guidance for individualized PPI prescribing in elderly patients, with careful benefit-risk assessment for those requiring extended-duration PPI regimens."

Adverse events • Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • ROR1

Development of Clinical Practice and Clinical Pharmacy Research toward the Appropriate Use of Medications (PubMed, Yakugaku Zasshi) - "The drug interaction that occurred between enteric-coated omeprazole tablets and Maalox® granules suggested the possibility of an unexpected drug interaction through a mechanism distinct from that reported for fluoroquinolones and Maalox® suspension. It has been suggested that aojiru strongly binds to cationic drugs with cyclic structures, significantly reducing their absorption. Based on these findings, we will continue to conduct pharmaceutical research in clinical practice and promote the appropriate use of medications."

Journal • Review